Profit from the Medicinal Cannabis Revolution

Dear Money & Crisis Reader,

Here’s the undeniable truth:

Marijuana legalization is coming to the United States.

Over 60% of states have legalized marijuana in some form.

Canada just legalized marijuana nationwide.

According to polls, 66% of Americans are in favor of recreational legalization ― including a majority of Republicans and older voters. And 94% of people are in favor of legalization for medical use in the United States.

That’s nearly 19 out of 20 people.

When was the last time that many people agreed on anything in the United States?

It’s unheard of.

We’ve seen a drastic increase in voter support over the past several years, and both Republicans and Democrats want to make it happen.

The reason?

There’s too much gosh darn money to pass up.

Look at Colorado and Washington. When these states and several others legalized cannabis in 2016, hundreds of millions of dollars poured into the newborn marijuana industry.

James Altucher predicts that 2019 will be the year marijuana will be federally legalized. And even if it doesn’t happen this year… the rise of legal marijuana byproducts is going to be huge.

James reveals the driving force behind this legal marijuana revolution in today’s issue of Money & Crisis.

All the best,

Owen Sullivan

Owen Sullivan
Editor, Money & Crisis

P.S. This is just one of James’s major predictions for 2019. Tomorrow, James is hosting his 2019 Predictions Summit webinar. During this “live” broadcast, he’ll reveal his predictions for three breakthrough trends to make 10x your money in the new year.

You don’t need a credit card. It’s completely FREE for you to attend.

Just enter your email here to reserve your seat.


How to Profit from the Medicinal Cannabis Revolution


James AltucherHemp is officially legal throughout the United States.

Last month, Congress quietly passed an $867 billion Farm Bill. Then President Trump signed the legislation into law… making hemp cultivation and hemp-based products 100% legal at the federal level.

And according to a recent report issued by the Brightfield Group, the hemp-derived CBD market is expected to grow from an estimated $591 million in 2018 to as much as $22 billion by 2022.

(Editor’s note: CBD, or cannabidiol, is a hemp extract that’s being used to help treat medical problems including epileptic seizures, anxiety, inflammation, pain and even sleeplessness. And it’s non-intoxicating so there’s no actual high.)

But for all the excitement surrounding hemp’s future, there’s another industry that’s terrified of the legalization of hemp: Big Pharma.

According to Statista.com, total nominal spending on medicines in the U.S. has grown from $195 billion in 2002 to a whopping $450 billion in 2016.

That means medical marijuana and hemp-based CBD products represent a multi-billion-dollar threat to the pharmaceutical industry.

CBD manufacturers, some medically trained professionals, and an endless number of loyal CBD users claim that hemp-based products can relieve pain, reduce anxiety and depression, alleviate cancer-related symptoms, contain neuroprotective properties, aid in helping opioid abusers come clean, and even clear up acne.

And a flood of new scientific studies is showing promising research in support of CBD’s health benefits.

For instance…

A study published by the European Journal of Pain showed promising results — and no side effects — of CBD-based ointment applied to rats with arthritis.

Another study published by the National Center for Biotechnology Information (NCBI) indicated that CBD had positive effects on some symptoms of multiple sclerosis and chronic pain sufferers.

The Journal of Experimental Medicine reported in a study that CBD showed promise in reducing pain and inflammation.

But when it comes to the American consumer abandoning traditional opioid therapies, we still have ground to cover.

You see, journalists at StatNews.com asked public health experts at 10 universities to forecast what the opioid epidemic would look like over the next 10 years. And the views of these experts were anything but comforting.

Some believe that if potent synthetic opioids continue to spread over the next 10 years as rapidly as they have been recently, we could see a death toll that spikes to 250 opioid-related deaths per DAY.

The frequency of deaths related to opioid overdoses has already become so bad that in late May 2017, one Ohio coroner reported out of 13 bodies delivered in 24 hours, 12 were overdose victims.

It’s stories like these — as well as the influx of studies detailing the benefits of CBD — that will drive Big Pharma to enter an industry it hoped would never see the legal light of day.

Takeaway: The 2018 Farm Bill clears the way for hemp-based CBD manufacturers to grow their businesses without the threat of DEA or federal intervention. The public is becoming increasingly wary of turning to opioids for medical treatment.

And as the medically observed uses for CBD expand, the value associated with popular CBD brands by both Wall Street and potential Big Pharma acquirers will explode.

If you position yourself well ahead of the herd, you’ll be waiting to feed the Wall Street ducks when they come quacking.

Sincerely,

James Altucher

James Altucher

P.S. Do NOT…

I repeat… Do NOT buy any stocks before you see what I’m revealing at this event.

Find out why at my “2019 Predictions Summit”… which for a limited time, I’ve made FREE for you to attend.

During this “live” broadcast, I’ll reveal my predictions for three breakthrough trends to make 10x your money in the New Year.

But you must act quickly. Or you’ll miss out on the best opportunity to make your fortune in 2019. Click here for details.

Chris Campbell

Written By Owen Sullivan

Owen Sullivan isn’t a millionaire or one of the Wall Street elite. He was just one of the many folks who was hit hard when the housing bubble burst… and decided he was never going to let that happen again. Since then, he’s worked with industry experts to develop strategies and techniques to bulletproof his finances — and yours — against the next crisis. His methods don’t require years of financial experience. These are simple strategies that anyone can follow. After all, financial prepping shouldn’t be reserved for a select few.